Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649791 · ClinicalTrials.gov registry record · NA
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
A NA study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01649791 is a NA study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 8 participants.
The verdict
NCT01649791, a NA study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This clinical trial studies lenalidomide as chemoprevention in treating patients with high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease progression in patients with early stage B-cell chronic lymphocytic leukemia
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- OTHER pharmacological study
- PROCEDURE bone marrow aspiration
- PROCEDURE lymph node biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01649791
The ClinicalTrials.gov registry entry for NCT01649791 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01649791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01649791 about?
NCT01649791 is a clinical study titled "Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia". This clinical trial studies lenalidomide as chemoprevention in treating patients with high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease progression in patients with ear...
What is the current status of trial NCT01649791?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2010-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01649791?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), pharmacological study (OTHER), bone marrow aspiration (PROCEDURE), lymph node biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01649791?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.